MannKind sends insulin to FDA
The FDA rejected the drug three years ago when the manufacturer submitted data that predated an inhaler change.
Clearing the FDA would put Afrezza on previously trod ground. Pfizer abandoned its inhaled insulin Exubera following poor sales. Novo and Lilly have also left inhaled insulin efforts in the dust.